Oculis Reports Q2 2025 Financial Results, Provides Company Update
Published on August 25, 2025
ZUG, Switzerland—Oculis Holding AG, a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases, announced results for the second quarter ended June 30, 2025, and provided an overview of the company’s progress. As of June 30, 2025, Oculis reported holding cash, cash equivalents and short-term investments of $201.3 million, providing what the company said will provide a cash runway into early 2028. The company also reported a year-to-date net loss of $67.9 million for the six months ended June 30, 2025, compared with $41.5 million for the same period in 2024.